Lecanemab and Beyond: Shifting from Pharma Hype to Real Neuroprotective Care

A little over a year ago, I wrote an article expressing my opinion about the drug donanemab; at that time it was being promoted as a “BREAKTHROUGH” in Alzheimer’s research, but the scientific data did not support such expectations. Today, Lecanemab (Leqembi) has been approved by the European Commission to treat early‑stage Alzheimer’s disease. However, … Continue reading Lecanemab and Beyond: Shifting from Pharma Hype to Real Neuroprotective Care →

Depresión: La Epidemia del Siglo XXI

Antes de profundizar en este tema, es crucial considerar algunos datos clave: La depresión mayor es el trastorno neuropsiquiátrico más prevalente en nuestra sociedad y, a su vez, una de las principales causas de ausentismo laboral en el mundo. Su impacto trasciende el ámbito individual, afectando no solo la calidad de vida de quienes la … Continue reading Depresión: La Epidemia del Siglo XXI →

New Year, New Brain

A Chance for Renewal Maintaining the consistency needed to sustain certain habits has always been a challenge, and it will continue to be. Interestingly, this difficulty tends to increase the more important those habits are for our well-being trust me, I know! In moments like these, it’s easy to give in to the temptation of … Continue reading New Year, New Brain →

The Impact of Neuroprotection on Long-Term Mental Health During Global Crises.

When we talk about neuroprotection, it's natural to think of it in relation to conditions or treatments that impact human health, particularly mental well-being. However, what happens when the mental health of the world itself is at risk? Global crises, environmental stressors, and societal challenges can severely affect our collective cognitive resilience, that's why considering … Continue reading The Impact of Neuroprotection on Long-Term Mental Health During Global Crises. →